 | | |
| |
|
| |
|
Appointments
|
|
Attending Pathologist
|
|
Director Division Of Hematopathology
|
|
Professor of Pathology and Laboratory Medicine
|
|
Vice Chairman For Hematopathology
|
|
|
|
|
| |
Orazi, Attilio
| Pathology and Laboratory Medicine |
|
 (212) 746-2050  (212) 746-2009
Dr. Attilio Orazi, Professor of Pathology and Laboratory Medicine, serves as Vice Chairman for Hematopathology and Director, Division of Hematopathology. Dr. Orazi received his M.D. from the University of Milan in his native Italy. He completed postgraduate training in Hematology and Pathology in the United Kingdom and in Italy. Dr. Orazi is certified in Anatomic Pathology and in Hematology by the American Board of Pathology. Since emigrating to the United States, he has served as Professor of Pathology and Director of Hematopathology at the College of Physicians and Surgeons of Columbia University, in New York, and most recently in the same capacity, at the Indiana University School of Medicine.
Dr. Attilio Orazi is an internationally renowned academic hematopathologist whose diagnostic expertise spans all areas of hematopathology. However, he is best known for his expertise and scholarly accomplishments as a bone marrow pathologist. He is a member of the Scientific Committee of the European Bone Marrow Working Group, has directed courses concerning the assessment of bone marrow disorders and splenic pathology at the United States and Canadian Academy of Pathology and was the co-organizer of the 2007 Workshop of the Society of Hematopathology. Currently, Dr. Orazi is the main author or co-author in 14 chapter sections, including the vast majority of those concerning myeloid neoplastic disorders, in the upcoming 4th edition of the WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues. He has published more than 130 peer-reviewed papers, numerous textbook chapters and review articles and is one of the two authors of the prominent textbook Disorders of the Spleen.
His research program is focused on identifying distinctive immunologic and molecular genetic characteristics of hematologic neoplasms that are useful in their diagnosis, classification, and prognosis. Additionally, his group is interested in elucidating the mechanisms that are involved in the pathogenesis of hematologic malignancies. On-going projects include:
1) The investigation of genetic alterations associated with malignant lymphoma and multiple myeloma and their subsequent evaluation as potential diagnostic and prognostic indicators.
2) The investigation of the molecular genetic events that underlie and are responsible for the clinical progression and morphologic transformation from low grade malignancies to clinically aggressive diseases.
3) The identification of the molecular genetic events responsible for the development of lymphoproliferative disorders in organ transplant recipients and their progression from oligoclonal proliferations responsive to diminished immunosuppression to autonomous monoclonal proliferations unresponsive to therapy.
4) The elucidation of molecular genetic events involved in the pathogenesis of myelodysplastic, myeloproliferative, and other types of myeloid neoplasms. The relationship between the presence of these abnormalities and the clinicopathologic manifestations are evaluated in an attempt to clarify controversial issues relevant to disease classification and clinical management of these patients.
|
| |
|
| |
|
| |
|
|
|
| |
|
| Medical
Practice(s) |
Visit this physician's medical practice site for information
on: - Making an Appointment
- Office Hours
- Office Staff
- Directions
|
|
| |
| |
|
|
|
| Clinical
Expertise |
|
Hematopathology
|
|
Anatomic Pathology
|
|
|
|
| |
| |
|
| |
|
| |
|
Back to Top